In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel

Konishi, Mitsunaga; Tabata, Yasuhiko; Kariya, Masatoshi; Suzuki, Ayako; Mandai, Masaki; Nanbu, Kanako; Takakura, Kenji; Fujii, Shingo

doi:10.1016/s0168-3659(03)00364-x

Cited by 106 publications

(74 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because medgel was slowly resolved by collagenase in vivo, we can administrate omentin gradually for a long period of time. A previous report confirmed that the drug was sustained releasing from medgel for 14 days after implantation in vivo (7). In the in vitro preliminary experiment, we found that omentin in the medgel was released into water at 0.15 g/24 h. Based on the result, we applied 5 g omentin/ mouse in medgel.…”

Section: Methodssupporting

confidence: 75%

A novel adipocytokine, omentin, inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell migration through antioxidative mechanism

Kazama

Okada

Yamawaki

2014

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

Section: Methodssupporting

confidence: 75%

A novel adipocytokine, omentin, inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell migration through antioxidative mechanism

Kazama

Okada

Yamawaki

2014

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

“…Though Doc-np by intratumoral administration cannot achieve as high initial concentration as free Doc, the sustained release of Doc is capable of delivering its antitumor efficacy constantly (27). As a result, it is highly reasonable that released Doc from the intratumorally delivered nanoparticles retain in the interstitial space of the tumor for a longer time compared to normal tissue and exerts protracted tumor-eliminating effect locally (28). Besides, the relatively lower drug concentration in plasma by local delivery, compared to systemic administration, means less toxicity to normal tissues.…”

Section: Discussionmentioning

confidence: 99%

Enhanced antitumor efficiency of docetaxel-loaded nanoparticles in a human ovarian xenograft model with lower systemic toxicities by intratumoral delivery

Zheng

Li²,

Lu³

et al. 2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. As successful chemotherapy with the taxanes needs to reduce the toxic side effects against normal tissues and avoid the detrimental effects caused by intolerable solvents, drug delivery system using soluble polymeric micelles tends to be the focus. Docetaxel (Doc) has demonstrated extraordinary activities against a variety of solid tumors. However, the clinical efficacy is contrasted by its toxicity profile. To reduce the toxicity and enhance the circulation time of Doc, core-shell structure nanoparticles were prepared from block copolymer of methoxy poly(ethylene glycol)-polycaprolactone (mPEG-PCL). It was found that Doc can be incorporated into the nanoparticles with high encapsulation efficiency of more than 90%. In vitro release study showed that Doc was released from Doc-np in a sustained manner. In vitro cytotoxicity studies indicated that IC50 of docetaxelloaded nanoparticles (Doc-np) against SKOV3 cells is significantly lower than that of free Doc. Furthermore, intratumoral administration was applied to improve the tumor-targeted delivery in the in vivo evaluation. Compared with free Doc, Doc-np exhibited superior antitumor effect by delaying tumor growth when delivered intratumorally. Blood test, as well as liver and kidney function, showed that Doc-np had little toxicity while free Doc induce severe anemia and liver damage. These results suggest that Doc-np are effective in inhibiting the growth of human ovarian cancer with little toxicity to normal tissues, and intratumoral delivery of Doc-np could be a clinically useful therapeutic regimen and merit more research to evaluate the feasibility of clinical application.

show abstract

“…47), prodrug ( for review, see ref. 48) strategies, or the use of drug delivery systems such as hydrogel-based systems (49), may be made more effective by increasing local toxic effects against tumors with minimal damage to host immune systems. Before undertaking such treatments, the routes and doses of drugs need to be optimized.…”

Section: Discussionmentioning

confidence: 99%

Epigallocatechin-3-Gallate Enhances CD8+ T Cell–Mediated Antitumor Immunity Induced by DNA Vaccination

Lee²,

et al. 2007

View full text Add to dashboard Cite

Immunotherapy and chemotherapy are generally effective against small tumors in animal models of cancer. However, these treatment regimens are generally ineffective against large, bulky tumors. We have found that a multimodality treatment regimen using DNA vaccination in combination with chemotherapeutic agent epigallocatechin-3-gallate (EGCG), a compound found in green tea, is effective in inhibiting large tumor growth. EGCG was found to induce tumor cellular apoptosis in a dose-dependent manner. The combination of EGCG and DNA vaccination led to an enhanced tumor-specific T-cell immune response and enhanced antitumor effects, resulting in a higher cure rate than either immunotherapy or EGCG alone. In addition, combined DNA vaccination and oral EGCG treatment provided longterm antitumor protection in cured mice. Cured animals rejected a challenge of E7-expressing tumors, such as TC-1 and B16E7, but not a challenge of B16 7 weeks after the combined treatment, showing antigen-specific immune responses. These results suggest that multimodality treatment strategies, such as combining immunotherapy with a tumor-killing cancer drug, may be a more effective anticancer strategy than singlemodality treatments. [Cancer Res 2007;67(2):802-11]

show abstract

In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel

Cited by 106 publications

References 22 publications

A novel adipocytokine, omentin, inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell migration through antioxidative mechanism

A novel adipocytokine, omentin, inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell migration through antioxidative mechanism

Enhanced antitumor efficiency of docetaxel-loaded nanoparticles in a human ovarian xenograft model with lower systemic toxicities by intratumoral delivery

Epigallocatechin-3-Gallate Enhances CD8+ T Cell–Mediated Antitumor Immunity Induced by DNA Vaccination

Contact Info

Product

Resources

About